News


Research paper “Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms”, co-authored by MyeloPro, has been published in Blood.

 

May 09, 2019 – Vienna

 

Research paper “Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms”, co-authored by MyeloPro, has been published in Blood.

 

Using RNA sequencing performed on the tumor biopsy as a basis for target discovery, relevant targets could be identified and a variety of different mutation classes could be addressed. Fusions and splicing-related aberrations are the examples of such mutation classes, where RNA sequencing is the preferred method of their systematic discovery. Researchers were able to demonstrate that especially patients with mutations in the splicing factor SF3B1 and CALR genes produce a variety of tumor specific peptides. These altered peptides could serve as a blueprint for cancer vaccine production.

 

Reference

 

Fiorella Schischlik, Roland Jäger, Felix Rosebrock, Eva Hug, Michael K Schuster, Raimund Holly, Elisabeth Fuchs, Jelena D. Milosevic Feenstra, Edith Bogner, Bettina Gisslinger, Martin Schalling, Elisa Rumi, Daniela Pietra, Gottfried F Fischer, Ingrid Faé, Loan Vulliard, Jörg Menche, Torsten Haferlach, Manja Meggendorfer, Anna Stengel, Christoph Bock, Mario Cazzola, Heinz Gisslinger and Robert Kralovics. Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms. Blood 2019 :blood.2019000519; doi: https://doi.org/10.1182/blood.2019000519  

 


MyeloPro research results presented at plenary session of 2018 Annual ASH meeting in San-Diego

 

Dec 04, 2018 – Vienna and San Diego

 

Research on the role of mutant CALR as cytokine in myeloproliferative neoplasms, co-authored by MyeloPro and conducted using MyeloPro’s assays and materials, was prominently presented at 2018 Annual Meeting of American Society of Hematology in San Diego, California, Nov 30 – Dec 04. The abstract “Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy” was selected for the presentation at plenary session of the meeting and featured the further options of targeting mutant calreticulin with immunotherapy approaches.

 

 

 

Reference

 

Christian Pecquet, Thomas Balligand, Ilyas Chachoua, Anita Roy, Gaelle Vertenoeil, Didier Colau, Emanuel Fertig, Caroline Marty, Harini Nivarthi, Jean-Philippe Defour, Erica Xu, Eva Hug, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Carola Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Isabelle Plo, William Vainchenker, Robert Kralovics and Stefan N Constantinescu. Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood 2018 132:4; doi: https://doi.org/10.1182/blood-2018-99-118348

 


Early stage financing for MyeloPro

 

Friday, October 6, 2017

 

MyeloPro Diagnostics and Research GmbH (MyeloPro) obtains funding from the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice Gesellschaft (AWS SEED program) to complete discovery program of CALR targeting therapeutics and establish its infrastructure to face the start of preclinical development. Non-dilutive federal funding allows  to maintain independence and provides resources in addressing the high medical need of rare, orphan blood malignancies called myelopoliferative neoplasms (MPNs).

 

 

About MyeloPro

MyeloPro is a discovery stage, Vienna (Austria) based biopharmaceutical company, developing therapeutics to treat myeloproliferative neoplasms. MyeloPro obtained a worldwide, exclusive therapeutic license from CeMM of the Austrian Academy of Science to target the mutant form of calreticulin (CALR). MyeloPro is actively seeking private investor partners for preclinical development of its most promising development candidates.

 

Contact information

Oleh Zagrijtschuk, MD

General Manager

MyeloPro Diagnostics and Research GmbH

Lazarettgasse 14, BT25.3, CeMM building, level 3, 1090 Vienna

Phone: +43 664 882 62 093

Email: oleh.zagrijtschuk@myelopro.com


BIO-Europe Spring 2017

Meet MyeloPro at BIO-Europe Spring in Barcelona, March 20-22, 2017

 

Thursday, February 16, 2017

 

The founders of MyeloPro will attend the BIO-Europe partnering conference in Barcelona to present the company, find partners, service providers and secure future financing.

MyeloPro’s presentation: Tuesday 21st of March, 10:50am, Room 120, Level 1


MyeloPro acquires an exclusive worldwide license from CeMM to develop therapeutics targeting mutated calreticulin protein in malignant diseases

 

Wednesday, October 12, 2016

CALR mutations have been discovered by the research team of Robert Kralovics at CeMM as highly disease-specific markers to a blood cancer called myeloproliferative neoplasms (MPN). Recently, the relevance of CALR mutations have been recognized by the WHO, including them as one of the major diagnostic criteria.

 

As a unique, disease-specific peptide, mutated CALR is also an attractive target to develop therapies.  “This licensing agreement enables MyeloPro to continue research on the therapeutic exploitation of mutated CALR in a disease area with an unmet medical need. We are making progress and are very excited to partner with CeMM, a world-class research institution“, states Oleh Zagrijtschuk, CEO of MyeloPro. The above mentioned license agreement excludes diagnostic use of the CALR mutation.

The mission of CeMM is to achieve maximum innovation in precise and personalized molecular medicine to improve healthcare. A committed team of scientists and medical doctors pursue free basic research in the life sciences fully engrafted in a large and vibrant hospital environment of great medical tradition and practice. Partnerships with biotech or pharma companies facilitates following upon research results by providing solutions to medical doctors and patients.

 

References

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E,Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90.

 

2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloidneoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405